Find trials
Search tips

Renal Recovery After Impella 5.5 Placement in Patients With Cardiogenic Shock

Overview

About this study

The purpose of this study is to assess renal recovery after Impella 5.5 placement in patients with cardiogenic shock assessed by an increase in glomerular filtration rate, and a decrease in serum creatinine.
 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • All patients above the age of 18 who receive an Impella 5.5 in the setting of acute decompensated heart fialure will be included.

Exclusion criteria:

  • Patients younger than 18 years old or those who receive an Impella 5.5 for post-cardiotomy shock, left-ventricular vetn during veno-arterial extracorporeal membrane oxygenation (VA ECMO/EcPELLA) or those patients on renal replacement therapy (intermittent or continuous) prior to Impella placement will be excluded.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 6/6/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Rohan Goswami, M.D.

Contact us for the latest status

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20582081

Mayo Clinic Footer